Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The “rights” of precision drug development for Alzheimer’s disease
Jeffrey L. Cummings, Howard Feldman, Philip Scheltens
Alzheimer s Research & Therapy (2019) Vol. 11, Iss. 1
Open Access | Times Cited: 204

Showing 1-25 of 204 citing articles:

Blood-based biomarkers for Alzheimer's disease: towards clinical implementation
Charlotte E. Teunissen, Inge M.W. Verberk, Elisabeth H. Thijssen, et al.
The Lancet Neurology (2021) Vol. 21, Iss. 1, pp. 66-77
Open Access | Times Cited: 359
Gut Microbiota and Dysbiosis in Alzheimer’s Disease: Implications for Pathogenesis and Treatment
Shan Liu, Jiguo Gao, Mingqin Zhu, et al.
Molecular Neurobiology (2020) Vol. 57, Iss. 12, pp. 5026-5043
Open Access | Times Cited: 340
Alzheimer's disease drug development pipeline: 2023
Jeffrey L. Cummings, Yadi Zhou, Garam Lee, et al.
Alzheimer s & Dementia Translational Research & Clinical Interventions (2023) Vol. 9, Iss. 2
Open Access | Times Cited: 332
Comprehensive Evaluation of the 5XFAD Mouse Model for Preclinical Testing Applications: A MODEL-AD Study
Adrian L. Oblak, Peter Bor‐Chian Lin, Kevin P. Kotredes, et al.
Frontiers in Aging Neuroscience (2021) Vol. 13
Open Access | Times Cited: 227
Challenges and hopes for Alzheimer’s disease
Suren A. Tatulian
Drug Discovery Today (2022) Vol. 27, Iss. 4, pp. 1027-1043
Closed Access | Times Cited: 203
Aducanumab produced a clinically meaningful benefit in association with amyloid lowering
Jeffrey L. Cummings, Paul Aisen, Cynthia A. Lemere, et al.
Alzheimer s Research & Therapy (2021) Vol. 13, Iss. 1
Open Access | Times Cited: 190
New approaches to symptomatic treatments for Alzheimer’s disease
Jeffrey L. Cummings
Molecular Neurodegeneration (2021) Vol. 16, Iss. 1
Open Access | Times Cited: 164
Understanding multifactorial brain changes in type 2 diabetes: a biomarker perspective
Geert Jan Biessels, Flavio Nobili, Charlotte E. Teunissen, et al.
The Lancet Neurology (2020) Vol. 19, Iss. 8, pp. 699-710
Closed Access | Times Cited: 145
Role of chronic neuroinflammation in neuroplasticity and cognitive function: A hypothesis
Daniela Lecca, Yoo Jin Jung, Michael T. Scerba, et al.
Alzheimer s & Dementia (2022) Vol. 18, Iss. 11, pp. 2327-2340
Open Access | Times Cited: 127
The State of The Art on Acetylcholinesterase Inhibitors in the Treatment of Alzheimer’s Disease
Immacolata Vecchio, Luca Sorrentino, Anna Maria Paoletti, et al.
Journal of Central Nervous System Disease (2021) Vol. 13
Open Access | Times Cited: 112
Accelerating Alzheimer’s therapeutic development: The past and future of clinical trials
Adam L. Boxer, Reisa A. Sperling
Cell (2023) Vol. 186, Iss. 22, pp. 4757-4772
Open Access | Times Cited: 82
Poor Translatability of Biomedical Research Using Animals — A Narrative Review
Lindsay J. Marshall, Jarrod Bailey, Manuela Cassotta, et al.
Alternatives to Laboratory Animals (2023) Vol. 51, Iss. 2, pp. 102-135
Open Access | Times Cited: 64
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders
Jeffrey L. Cummings, Charlotte E. Teunissen, Brian Fiske, et al.
Nature Reviews Drug Discovery (2025)
Closed Access | Times Cited: 3
From combinations to multitarget‐directed ligands: A continuum in Alzheimer's disease polypharmacology
Claudia Albertini, Alessandra Salerno, Pedro de Sena Murteira Pinheiro, et al.
Medicinal Research Reviews (2020) Vol. 41, Iss. 5, pp. 2606-2633
Closed Access | Times Cited: 129
Dysfunction of ABC transporters at the blood-brain barrier: Role in neurological disorders
Eva Gil-Martins, Daniel José Barbosa, Vera Silva, et al.
Pharmacology & Therapeutics (2020) Vol. 213, pp. 107554-107554
Closed Access | Times Cited: 121
The promise of microRNA-based therapies in Alzheimer’s disease: challenges and perspectives
Hannah Walgrave, Lujia Zhou, Bart De Strooper, et al.
Molecular Neurodegeneration (2021) Vol. 16, Iss. 1
Open Access | Times Cited: 91
Blood-Brain Barrier Opening with MRI-guided Focused Ultrasound Elicits Meningeal Venous Permeability in Humans with Early Alzheimer Disease
Rashi I. Mehta, Jeffrey Carpenter, Rupal I. Mehta, et al.
Radiology (2021) Vol. 298, Iss. 3, pp. 654-662
Open Access | Times Cited: 88
Alzheimer’s disease beyond amyloid: Can the repetitive failures of amyloid-targeted therapeutics inform future approaches to dementia drug discovery?
Kevin Mullane, Michael Williams
Biochemical Pharmacology (2020) Vol. 177, pp. 113945-113945
Closed Access | Times Cited: 86
The Alzheimer’s disease drug development landscape
Pieter van Bokhoven, Arno de Wilde, Lisa Vermunt, et al.
Alzheimer s Research & Therapy (2021) Vol. 13, Iss. 1
Open Access | Times Cited: 83
Prevention of Early Alzheimer’s Disease by Erinacine A-Enriched Hericium erinaceus Mycelia Pilot Double-Blind Placebo-Controlled Study
I-Chen Li, Han‐Hsin Chang, Chuan‐Han Lin, et al.
Frontiers in Aging Neuroscience (2020) Vol. 12
Open Access | Times Cited: 79
Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing
Jiansong Fang, Andrew A. Pieper, Ruth Nussinov, et al.
Medicinal Research Reviews (2020) Vol. 40, Iss. 6, pp. 2386-2426
Open Access | Times Cited: 79
Beyond the average patient: how neuroimaging models can address heterogeneity in dementia
Serena Verdi, André F. Marquand, Jonathan M. Schott, et al.
Brain (2021) Vol. 144, Iss. 10, pp. 2946-2953
Open Access | Times Cited: 73
AlzGPS: a genome-wide positioning systems platform to catalyze multi-omics for Alzheimer’s drug discovery
Yadi Zhou, Jiansong Fang, Lynn M. Bekris, et al.
Alzheimer s Research & Therapy (2021) Vol. 13, Iss. 1
Open Access | Times Cited: 70
Aducanumab: a new phase in therapeutic development for Alzheimer’s disease?
Giovanna Lalli, Jonathan M. Schott, John Hardy, et al.
EMBO Molecular Medicine (2021) Vol. 13, Iss. 8
Open Access | Times Cited: 65
Role of miRNAs in Neurodegeneration: From Disease Cause to Tools of Biomarker Discovery and Therapeutics
Bidisha Roy, Erica Lee, Teresa Li, et al.
Genes (2022) Vol. 13, Iss. 3, pp. 425-425
Open Access | Times Cited: 63
Page 1 - Next Page

Scroll to top